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Abstract 
Investigative Toxicology describes the de-risking and mechanistic elucidation of toxicities, supporting early safety 
decisions in the pharmaceutical industry. Recently, Investigative Toxicology has contributed to a shift in 
pharmaceutical toxicology, from a descriptive to an evidence-based, mechanistic discipline. This was triggered by 
high costs and low throughput of Good Laboratory Practice in vivo studies, and increasing demands for adhering 
to the 3R (Replacement, Reduction and Refinement) principles of animal welfare. Outside the boundaries of 
regulatory toxicology, Investigative Toxicology has the flexibility to embrace new technologies, enhancing 
translational steps from in silico, in vitro to in vivo mechanistic understanding to eventually predict human response. 
One major goal of Investigative Toxicology is improving preclinical decisions, which coincides with the concept of 
animal-free safety testing. Currently, compounds under preclinical development are being discarded due to the use 
of inappropriate animal models . Progress in Investigative Toxicology could lead to humanized in vitro test systems 
and the development of medicines less reliant on animal tests. To advance this field a group of 14 European-based 
leaders from the pharmaceutical industry founded the Investigative Toxicology Leaders Forum (ITLF), an open, 
non-exclusive and pre-competitive group that shares knowledge and experience. The ITLF collaborated with the 
Centre for Alternatives to Animal Testing Europe (CAAT-Europe) to organize an "Investigative Toxicology Think-
Tank", which aimed to enhance the interaction with experts from academia and regulatory bodies in the field. 
Summarizing the topics and discussion of the workshop, this article highlights Investigative Toxicology’s position by 
identifying key challenges and perspectives. 
                                                          
* A report of t4 – the transatlantic think tank for toxicology, a collaboration of the toxicologically oriented chairs in Baltimore, 
Konstanz and Utrecht sponsored by the Doerenkamp-Zbinden Foundation. The present report is the output of a three-day 
workshop sponsored by CAAT-Europe and Investigative Toxicology Leaders Forum (ITLF) held in Ranco (Italy) on July 10-12, 
2017. The concepts and ideas presented here come from the individual participants and do not reflect the views and opinions of 
the organizations that they are representing. The debates were based on scientific discussions among the participants, without 
necessarily unanimous final agreement. 
§ Members of the Investigative Toxicology Leaders Forum (ITLF) 
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1 Introduction1
 
Tremendous progress in preclinical development across the pharmaceutical industry has been achieved over the last three 
decades. This pivotal phase, which prepares the transition into First-in-Man trials, has been strongly harmonized under the 
umbrella of the International Conference for Harmonisation (ICH) of Technical Requirements for Pharmaceuticals for 
Human Use (Ohno, 2002; ICH, 2013). The ICH has contributed to an internationally accepted set of submission relevant 
guideline documents generally concerning in vivo drug safety studies, which are based on OECD (The Organisation for 
Economic Co-operation and Development) test guidelines for the individual study conduct and strongly connected to OECD 
documents for GLP (Good Laboratory Practice). The whole framework of harmonization has led to an increase of mutual 
acceptance of preclinical submission documents in the three regions involved (European Union, the United States and Japan) 
and as a consequence to an elimination of studies performed to satisfy the specific requirements of individual regulatory 
authorities (OECD, 2005). 
 This positive development of streamlined testing strategies, however, also brought forth some challenges. In many 
companies, there is a reluctance to integrate new technologies or assays next to the established safety assessment consisting 
of GLP in vivo studies due to the perception that non-GLP, or not fully validated assays, might compromise the pivotal 
studies and endanger the approval process. The high standard of harmonization and validation developed for the GLP studies 
is often requested for new technologies and assays. On the other hand, the attrition due to safety reasons in preclinical and 
clinical drug development phases still represents a major factor for the overall loss of projects and there is pressure for 
improving the predictive power of preclinical studies, including new screening strategies. In addition, the high costs and the 
rather low throughput of the GLP in vivo studies and the intensified demands for addressing the 3Rs has increased the push 
for new screening strategies (Sewell et al., 2017). As a consequence, most pharmaceutical companies have established 
specific toxicology functions, which complement the experimental GLP functions. Some companies have even gone so far as 
to fully outsource the GLP activities and to focus in-house on preclinical safety activities to what is termed "discovery", 
"exploratory", "mechanistic" or "investigative" toxicology. While the tasks and organizational set-up of these functions differ 
from company to company, it has become evident that the value of these activities does not only lie in screening assays 
preceding the regulatory activities, but also in the enhanced understanding of the mechanism of toxicity which is equally 
relevant for later phases of clinical development. In fact, this shifts pharmaceutical toxicology from a purely descriptive to an 
evidence-based mechanistic discipline. For this reason, the authors of this publication prefer the term "Investigative 
Toxicology" over "discovery toxicology" since it avoids the perceptional limitations to only serve the early phases of safety 
assessment. The continuum of Investigational Toxicology in the drug development process is illustrated in Figure 1. Thus, 
from a pharmaceutical industry point of view, the term ‘Investigative Toxicology’ can be defined as the complementary 
effort to regulatory toxicology encompassing a prospective approach (screening for de-risking) and a retrospective approach 
(mechanistic investigations of adverse effects) (Moggs et al., 2012). 
 To foster awareness, development and implementation of investigational toxicology and to share expertise, 
knowledge and best practice in a pre-competitive space, a group of European-based Investigative Toxicology leaders from 
the pharmaceutical industry (see Figure 2 for participating companies) founded the Investigative Toxicology Leaders Forum 
(ITLF) (Roth, 2017). This open, non-exclusive forum also aims to enhance the interaction with experts from academia and 
regulatory bodies in the field of Investigative Toxicology.  
 The objective of the ITLF is to elaborate robust, reliable and accepted Investigative Toxicology concepts and 
practices for decision-making for early safety-related attrition, de-risking, and mechanistic elucidation of effects as shown in 
Figure 3. The figure illustrates how Investigative Toxicology adds to the traditional drug development process. Investigative 
Toxicology supports the entire process through early assessments of target- and chemical class-related toxicological concerns 
and front-loading of assessments as prospective risk anticipation. Furthermore, alerts from later stages of development and 
market surveillance can trigger a retrospective de-risking process, which will typically include the elucidation of toxic 
mechanisms to assess its relevance to humans and possible mitigation strategies. 
                                                          
1 Abbreviations  
3D – three dimensional; 3Rs – refine, reduce, replace; ADR - adverse drug reaction; AI – artificial intelligence; ALP - alkaline 
phosphatase; ALT – alanine aminotransferase; AOPs - adverse outcome pathways; ASO - anti-sense oligonucleotide; AST – 
aspartate aminotransferase; BAEP, brain auditory evoked response; BIL – bilirubin; BNP - brain natriuretic peptide; CAAT-
Europe - Centre for Alternatives to Animal Testing Europe; ChIP - chromatin-immunoprecipitation; CIPA - comprehensive in 
vitro pro-arrhythmic assay; CK – creatine kinase; CNS – central nervous system; CRS - cytokine release syndrome; CSF - 
cerebrospinal fluid; DDI - drug-drug interaction; DILI - drug-induced liver injuries; DMPK - drug metabolism and 
pharmacokinetics; EC - endothelial cells; ECG – electrocardiogram; EEG - electroencephalogram; EFPIA, European Federation 
of Pharmaceutical Industries and Associations; EMA – European Medicines Agency; ERG - electroretinogram; FDA – Food and 
Drug Administration; GCCP – Good Cell Culture Practice; GFP - green fluorescent protein; GIVIMP - Good In Vitro Method 
Practices; GLP - Good Laboratory Practice; HMGB1 - high mobility group box 1; HTS – high-throughput screening; IATA – 
integrated approaches to testing and assessment; ICH - International Conference for Harmonisation of Technical Requirements 
for Pharmaceuticals for Human Use; IMI - Innovative Medicines Initiative; iPSC – induced pluripotent stem cells; ITLF - 
Investigative Toxicology Leaders Forum; ITS – integrated testing strategy; IVIVE, in vitro-in vivo extrapolation; JRC, Joint 
Research Center; KE - key event; LC - liquid chromatography; LLNA - local lymph node assay; MIE - molecular initiating event; 
MoA - mode of action; MPS - microphysiological system; MS – mass spectrometry; NBE - new biological entity; NCE - new 
chemical entity; NOAEL - no observed adverse effect level; NT-proBNP - N-terminal pro brain natriuretic peptide; OECD - The 
Organisation for Economic Co-operation and Development; PBPK – physiology-based pharmacokinetic modeling; PKPD - 
pharmacokinetics and pharmacodynamics; PoD - point of departure; PoT - pathways of toxicity; pro-ANP - pro-atrial natriuretic 
peptide; QIVIVE - quantitative in vitro to in vivo extrapolations; (Q)SAR – (quantitative) structure activity relationships; R&D – 
research and development; TKTD - toxicokinetics and toxicodynamics; WoE - weight of evidence 
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Fig. 1: A visual illustration of the continuum of Investigative Toxicology in the drug discovery and development 
pipeline 
Plain arrows represent the forward feed information to move to next step, while dashed arrows represent back feed of 
knowledge to improve systems predictivity. Organ-on-chip, 3D tissues and MPS have the potential to complement and perhaps 
to some extent, replace certain steps of research and development. FiH, First-in-Human trial; MPS, microphysiological systems; 
M&S, modeling and simulation. 
 
Fig. 2: Companies participating in the pre-competitive Investigative 
Toxicology Leaders Forum (ITLF) as of July 2018  
Objectives of the ITLF are to jointly elaborate robust, reliable and accepted 
Investigative Toxicology concepts for decision making for early safety-
related attrition, de-risking, and mechanistic elucidation of safety-related 
effects, to increase the understanding and improve the translation of in vitro 
to in vivo mechanistic data. Furthermore, the adoption of new 
technologies/platforms into the drug discovery back-bone is targeted by the 
forum, to increase the knowledge and awareness on Investigative 
Toxicology as a discipline (e.g. through publications, meetings and 
conferences). 
  
 
 
 
 
 
 
 
 
The goal of Investigative Toxicology is improved preclinical decision making, but also coincides with the notion of an 
animal-free safety testing. Currently, many compounds are ruled out by animal models during the preclinical phase, without 
knowledge of how the compounds would behave in humans, i.e. the false-positive rate of animal studies cannot be assessed. 
In addition, significant attrition occurs in clinical phases due to safety issues not adequately identified during the preclinical 
phase (false negative) (Waring et al., 2015). Progress in Investigative Toxicology could lead to humanized in vitro test 
systems and thus towards the development of medicines without animal tests. For this reason, the ITLF teamed up with 
CAAT-Europe to organize an "Investigative Toxicology Think Tank". This Think Tank took place in July 2017 and 
assembled 34 experts from academia, the pharmaceutical and other industries, regulatory authorities and technology 
providers to develop a definition of Investigative Toxicology and to align academic and expert stakeholders with the needs 
for predictive and mechanistic investigational toxicology. Although the focus of this Think Tank was on Investigative 
Toxicology in drug development, progress in this field will also influence safety assessment in other industry sectors 
(industrial, consumer or agro-chemical compounds). This report represents a position paper for Investigative Toxicology 
based on the topics and discussions during the workshop. It starts with a gap analysis, followed by a critical assessment of 
new technologies and finishing with summarizing challenges, perspectives and concluding recommendations. 
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Fig. 3: Key objectives of Investigative 
Toxicology during drug discovery and 
development 
 
 
 
 
 
 
 
 
 
 
 
 
 
2 Gap analysis 
 
The pharmaceutical industry has made substantial efforts towards the implementation of in vitro-based models, which has 
improved hazard identification and risk assessment of drug candidates prior to non-clinical development (Hornberg et al., 
2014a, 2014b; Goh et al., 2015). However, much remains to be accomplished to address the substantial gaps in our 
mechanistic understanding of adverse drug reactions (ADRs) and to support the innovation of biomedical tools that are truly 
predictive of inter-individual human susceptibility to ADRs. The rapid “design-make-test-analyze” cycle times in drug 
discovery also places greater emphasis to further the understanding of the mechanisms of toxicity and chemical liabilities and 
to facilitate the decision-making processes on candidate selection and development of new chemical entities (NCEs) and new 
biological entities (NBEs). In addition, the increasing diversity of biopharmaceutics, which include cell and gene therapies, 
chimeric antigen receptor T (CAR-T) cells and vectors, antibodies and Anti-Sense Oligonucleotides (ASOs) presents new 
and significant risks, such as Cytokine Release Syndrome (CRS) and tissue cross reactivity issues, with a variety of new 
challenges in developing our testing strategies (Brennan et al., 2015; Dixit and Boelsterli, 2007; Bussiere et al., 2009). The 
following outlines the perceived gaps contributing to identifying NCE/NBE hazards for target-organ toxicities, limitations of 
risk assessments and predicting human safety, mitigation strategies to manage risk and current governance for investigative 
toxicological sciences. The mechanisms of ADRs are extensively reviewed elsewhere (Atienzar et al., 2016; Hornberg et al., 
2014a, 2014b). 
 
2.1 Hazard identification and risk assessment 
 
2.1.1 Target organ toxicity and models 
Although 70% of human relevant toxicities are detected in experimental species (Olson et al., 2000) the translational 
relevance of these toxicities is highly dependent on the target-organ affected. Significant human ADRs are predominantly 
associated with liver, heart and neurological organs (Cook et al., 2014; Olson et al., 2000; Sacks et al., 2014). The detection 
of dose-dependent drug hepatocellular cytotoxicity by in vitro cell-based models and animal studies is well accepted (Antoine 
et al., 2013; Ward et al., 2014), yet the multifactorial nature of drug induced liver injury (DILI) and known species 
differences are notable gaps, requiring the development of humanized models for the detection of liver injuries associated 
with immune or patient specific susceptibilities. For the identification of cardiovascular drug liabilities the concomitant use 
of both in vitro models and with animal studies is well established (Laverty et al., 2011; Valentin et al., 2010). Whereas 
effects on ion channels can be easily identified by in vitro (e.g. patch clamp) models, the complex interplay between heart 
rate, ejection volume and blood pressure eventually causing heart or kidney damage can currently only be assessed by in vivo 
models. Similarly, the early in vitro prediction of neurological ADR is still challenging as many side effects can often only be 
detected in clinical trials since they are caused by interactions with rare targets or occur only after chronic administration, 
which is difficult to achieve in in vitro assays (Schmidt et al., 2017). Regarding other toxicities such as hematologic or 
hematopoietic disorders or carcinogenic risk, few in vitro models exist due to the nature and complexity of the underlying 
pathology (see Table 1). However, there is a surge in development of organotypic and micro-physiological systems (MPS) 
(Marx et al., 2016) including multiple organ systems. There are high expectations for improved detection of drug liabilities 
for use in safety assessment by the use of these innovative 3D (three dimensional) models (Hardwick et al., 2017; Lin et al., 
2015; Mueller et al., 2014; Soldatow et al., 2013). 
 
2.1.2 Disease models 
Disease models are required to emulate organ-level functions and recapitulate key phenotypic features of human disease in 
cell or tissue-based as well as conventional and transgenic animal models. Disease status can impact considerably on the 
toxicity of substances and thus the target population of a novel drug candidate. Nevertheless, animal models established to 
reflect human disease often appear to have had limited success (Benam et al., 2015; Morgan et al., 2013) and likely 
contribute to the poor predictivity of efficacy and safety of drugs in later human clinical trials. The future incorporation and 
use of humanized in vitro disease models into toxicity assessments has the potential to concomitantly facilitate 
pharmacological discovery and safety evaluation of drugs (Hübner et al. 2018). This will improve the identification of safety 
margins with the potential to extrapolate phenotypic differences in patient populations and lead to mechanistically-driven 
safety margins in patient populations. 
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Table 1: Categories of safety attrition challenges 
Attrition Organ 
Discovery 
Cell & tissue-based models 
Non-
clinical 
(tox 
species) 
Translational value of models & 
gaps 
Hazard 
Risk 
assessment 
Predictive 
High Heart • • • • (1) 
Relatively good for detection and 
prediction of functional changes 
but limited in relation to structural 
changes.  
 
High 
 
Liver 
Hepatocellular •  • • (2) 
Relatively good concordance 
between hepatocellular injury 
IVIVE (in vitro-in vivo 
extrapolation) and liver injury in 
human. 
Cholestasis 
(acute) 
• x • x 
Animal models are poorly 
predictive of cholestasis  
High CNS  x x • (1,2) 
Models available for behavior, 
seizures, drug abuse; no models 
for cognition, suicidal ideation 
Medium Gastrointestinal  x x  
Limited to poor models detection 
and prediction 
Medium Kidney  x x • (1,2) 
Translational biomarkers permit ID 
of injury in animal models 
Medium Immune system x x x x 
Hypersensitivity reactions – poor. 
No tests are yet available for 
testing ab initio in Drug discovery 
or non-clinical testing 
Low Lung • • • • (1,2) Relatively good 
Low Haematology x x x • (1,2) 
No in vitro model, yet good in vivo 
concordance animal - Human 
Low Haemopoiesis x x x • (1,2) 
No in vitro model, yet good in vivo 
concordance animal - Human 
Low 
Skin 
(irritation/sensitisation) 
• •  • (2,3) 
In vitro models available with in 
vivo confirmatory and/or studies 
Medium 
Reproductive organs 
& embryofoetal 
development 
x x x 
 
• (2) 
Relatively good models for 
detection and prediction of 
embryo-foetal toxicities, but 
limited in relation to reproductive 
organs. 
Low 
Genetic toxicity & 
Carcinogenicity 
• /  x • /  • (2) 
In vitro models good for detection 
and prediction of genetic toxicity 
but poor for carcinogenicity risk 
identification 
x = no model, o = models yet to be evaluated for application in drug R&D, • = models routinely available/in use.  
1 – large species (dog or monkey); 2 – rodent; 3 – lagomorph 
 
2.1.3 Safety margins 
Dose limiting toxicity and the No Adverse Effect Level (NOAEL) define safety margins3 and toxicological profile for risk-
benefit of a drug candidate (Center for Drug Evaluation and Research, 2005). However, the NOAEL is often a subjective 
assessment of a biochemical or histopathological change on which to establish a safety margin (Dorato and Engelhardt, 
2005). In the absence of well-characterized safety biomarkers4 with clearly defined mechanistic and translational relevance to 
humans, preclinical findings in animals will, at best, only permit rough estimates of the safety margins. The pre-requisite for 
non-clinical safety testing is to select candidate drugs with large safety margins to improve the likelihood of clinical success. 
However, in vivo toxicological and clinical findings can result in unexpected and reduced safety margins in target organs 
during the clinical phase. Progress towards the identification of novel sensitive biomarkers with mechanistic and translational 
relevance may help to improve the monitoring of drug safety profiles. Better understanding of mechanistic toxicokinetics and 
toxicodynamics (TKTD) relationships in combination with pharmacokinetics and pharmacodynamics (PKPD) should 
establish an improved quantitative monitoring of safety margins in non-clinical and clinical research. 
                                                          
3 In other, non-pharma sectors, the common expression is "margin of safety" (MoS). Instead of NOAEL, which is the highest 
experimental dose in an in vivo study that is without observable adverse effect, the benchmark Dose Lower Confidence Limit 
based on benchmark dose modelling (BMDL) is more frequently used in these sectors. 
4 A biomarker is a defined characteristic that is measured as an indicator of normal biological processes, pathogenic processes, 
or responses to an exposure or intervention, including therapeutic interventions. Molecular, histologic, radiographic, or 
physiologic characteristics are types of biomarkers. Safety biomarkers are applied to indicate the likelihood, presence, or 
extent of toxicity as an adverse effect (for definitions see: 
https://www.fda.gov/Drugs/DevelopmentApprovalProcess/DrugDevelopmentToolsQualificationProgram/BiomarkerQualificatio
nProgram/default.htm). 
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2.2 Predicting human safety with mechanistic insight  
 
2.2.1 Adverse outcome pathways and pathways of toxicity  
The organization of mechanistic knowledge into temporal events includes pathways of toxicity (PoT) (Kleensang, 2014), 
mode of action (MoA) and Adverse Outcome Pathways (AOPs) (Ankley et al. 2010; Burden et al., 2015, Villeneuve et al. 
2014). An AOP describes a sequential chain of causally linked events at different levels of biological organisation that lead to 
an adverse effect on human health. AOPs best define the qualitative organization of information, whilst PoT relates more to 
quantitative, dynamic and molecularly defined systems. The application of AOPs with an understanding of mechanisms can 
help adopt novel biomarkers for use in the identification and monitoring of safety signals. Nevertheless, these are of limited 
value unless signals identified in in vitro and animal models can be linked to human ADRs through either target-based or 
phenotypic-based testing as weight of evidence (WoE) to facilitate improved risk assessment of human target organ 
toxicities. 
 
2.2.2 Idiosyncratic and hypersensitivity reactions  
Difficulties in the detection of hypersensitivity reactions and idiosyncratic toxicities arise due to ADR events that often occur 
already at low therapeutic dose levels in only small numbers of individuals during clinical development or post-registration 
(Pallardy and Bechara, 2017; Park et al., 2000; Uetrecht, 2013). The ‘non-existence’ of relevant humanized pre-clinical 
models for early testing of drug candidates, coupled with the absence of clear dose-related toxicities and complex 
dimensionality of immune-drug response necessitates urgent research to establish innovative diagnostic assays for drug 
discovery and continued efforts towards understanding mechanisms to support research and development of safer drugs. A 
successful example of such research is the specific case of hypersensitivity, namely skin sensitization, where the application 
of the AOP concept has led to a series of approved in vitro assays replacing the animal studies (OECD, 2014) 
 
2.2.3 Translational gap 
Significant gaps remain towards achieving fully integrated and characterized humanized organ-specific panel(s) of in vitro 
models. Use of such models will require arrays of qualified mechanistic translational safety biomarkers, while dose 
(exposure) dependent toxicities will continue to rely on observational or phenomenological-based endpoint tests, and WoE 
approaches to assess human drug safety (see above). Therefore, much work remains to be done towards establishing the next 
generation of in vitro models for target-organ safety testing. This includes the identification of novel safety biomarkers with 
translational value from early in vitro safety assessment to non-clinical as well as clinical safety assessment. More recently, 
gene editing technologies such as CRISPR/Cas9 have allowed refined engineering of animal disease models. For example, 
pig models have been established for cystic fibrosis, which are reported to be superior compared to the existing mouse 
models regarding the similarity to the human phenotype (Klymiuk et al., 2016). These technologies have the potential to 
bridge the gap between proof-of-concept studies in animals and clinical trials in patients, thus supporting translational 
medicine. 
 
2.2.4 Monitoring safety signals 
Biomarkers permit identification and monitoring of potential safety signals (see chapter 3.2) employing a broad spectrum of 
technologies. Biomarkers using imaging and molecular techniques have advanced in recent years for on-target and off-target 
assessments. Despite a rapid rise in the use of ‘omics technologies, several challenges remain until their routine adoption and 
application (Khan et al., 2014). For example, genomic and pharmacogenomic screening have found use in clinical trial 
enrolment for an indirect assessment of drug metabolizing enzyme activity, yet the measurements of enzyme activity and 
drug-drug interaction (DDI) (Ward et al., 2014) only results in predictive values of around 40% when relying on protein and 
transcriptomic data alone (Weaver, 2001). By contrast, transcriptomics has yielded more success for the detection of organ 
specific or selective pathologies (Chen et al., 2012), but nevertheless only appears to share similar sensitivity to those of 
established biomarkers (Zhang et al., 2012). Further limitations in the use and implementation of '-omics is the current need 
of invasive biopsies. 
 
2.2.5 Data Transparency 
The conduct and design of experimental studies has often drawn criticism due to the incompleteness of published data and 
the lack of reproducibility of results. In addition, the lack of data standards, missing definitions and lacking of ontologies 
represent a major hurdle for modelling and simulation exercises. However, the reuse and sharing of available public and 
private data, both within and across organizations, is progressively recognized as valuable source of information for read-
across, hazard identification and risk mitigation. The described hurdles are increasingly addressed through data governance 
frameworks. These efforts towards harmonization of study design, data curation and controls are more widely applied with 
public and public-private data repositories (Steger-Hartmann and Pognan, 2018). With the rapid expansion of data 
repositories, pharmaceutical companies’ decision-making process increasingly relies on these data to help support and 
complement internal research programs. EFPIA (European Federation of Pharmaceutical Industries and Associations) 
activities to facilitate data-sharing across companies will equally encourage high-value projects for cooperative data-sharing, 
which in-turn are likely drivers towards greater harmonization of operating protocols, and use and re-use of data in support of 
public health and drug research. 
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3 New technologies 
 
The development of improved, innovative models for the detection of toxicity of drugs, industrial or consumer chemical 
products is crucial to efficiently bring new products safely to the market in a cost-effective and timely manner. Figure 4 
illustrates some of the modern technologies going into Investigative Toxicology. 
This non-exhaustive list of technologies – especially in combinations -, encompasses a strong toolbox for mechanism-
based human-relevant Investigative Toxicology approaches. 
 
Fig. 4: Enabling technologies for 
Investigative Toxicology  
AI – artificial intelligence; AOP - Adverse 
Outcome Pathway; GCCP – Good Cell 
Culture Practice; HTS – High-throughput 
Screening; IATA – Integrated 
Approaches to Testing and Assessment; 
ITS – Integrated Testing Strategy; MoA - 
Mode of Action; MPS - 
microphysiological systems; PBPK – 
Physiology-based Pharmacokinetic 
modeling; PoT - Pathways of Toxicity; 
(Q)SAR – (quantitative) structure activity 
relationships 
 
 
 
 
3.1 In silico tools and modeling 
 
3.1.1 Overview 
The prediction of mutagenic activity of new chemical entities (NCEs) based on their structure and potential reactivity 
towards DNA has been used for some decades and in silico tools are now accepted for regulatory decision-making in the area 
of genotoxicity of drug candidates and impurities in pharmaceuticals (Amberg et al., 2014). Beside this, a lot of effort has 
been put into the prediction of organ toxicities, such as DILI, using different computational models (Kotsampasakou et al., 
2017; Mulliner et al., 2016a), which achieved accuracies in the range of 70 and 80 %. 
 New perspectives for in silico, read-across and modeling approaches are resulting from the emerging availability of 
big data in toxicology (Hartung, 2016; Clark and Steger-Hartmann, 2018). One opportunity to push investigative 
toxicologists to embrace the 3Rs principles relies on developing new in silico approaches, and also on effectively integrating 
existing in silico tools with in vitro technologies, as well as with preclinical and clinical databases (Rovida et al., 2015), 
conceivably within an AOP-like framework (Tollefsen et al., 2014). For example, the in silico prediction of on/off target 
liabilities was, in part, addressed in the Innovative Medicines Initiative (IMI) project, eTOX5. Predictive models were built in 
order to cover hundreds of clinical safety events linked to drugs and their pharmacological properties (Garcia-Serna et al., 
2015). Linking different data sources (toxicity, target and off-target, Drug Metabolism and Pharmacokinetics) (DMPK) using 
computational methods will allow toxicologists to go beyond the traditional structural alerts and moves towards an 
understanding of toxicity cascades. This could eventually contribute to AOP development or validation and ultimately to the 
interpretation of the underlying mechanism(s). The multifactorial origin of drug toxicity can thus be analyzed by combined 
approaches or network models to identify the causality of a toxic effect, ultimately shedding light on the likely mechanisms 
by which NCEs generated a safety risk. 
 
3.1.2 Machine learning and artificial intelligence 
A number of recent developments in quantitative pharmacology modelling have the potential to further embed these tools 
into an in silico drug development framework thus contributing to an early assessment of drug candidates regarding the 
differentiation between target or off-target related liabilities (Murphy, 2011). The standardization and automation of the 
development of quantitative pharmacology models, together with their validation and reporting, will facilitate the acceptance 
and uptake of QSARs (Kausar and Falcao, 2018). 
 As a compliment to the traditional QSAR models relating a chemical to a biological property, molecular docking 
models have allowed for the rapid calculation of the binding potential of drugs to a target protein. Studies assessing the 
performance of commonly used molecular docking programs (e.g. Glide, GOLD, FlexX, eHiTS, PDBbind database) indicate 
that these programs can perform precise protein conformation, but their scoring functions are still too inaccurate for a reliable 
prediction across a variety of targets (Plewczynski and Klingström, 2011). 
 There have been significant advances in machine or deep learning technology in recent years. Although deep 
learning approaches have been shown to yield accurate predictions (Mayr et al., 2016), they require large, costly datasets. 
                                                          
5 http://www.etoxproject.eu 
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When it is practical to generate a relatively small dataset, often researchers seek to test a diverse set of compounds in their 
assay. Because of the complexity of compound space as well as the assay results within that space, diversity selection of 
compounds does not always yield an optimally predictive model. One solution to this problem is the use of transfer learning. 
With this approach, data from biologically similar assays can be used to predict one another. This allows for the effective 
expansion of chemical space for toxicities for which data are more limited (Kangas et al., 2014). The second solution to the 
problem of generating data for learning predictive models is the use of active machine learning (Murphy, 2011). In essence, a 
machine learning algorithm can be used to identify which tests will yield the most informative data. By focusing 
experimentation on primarily the informative experiments which yield the best data, the data from far fewer experiments are 
needed to learn an accurate predictive model. In practice, these active machine learning approaches can significantly reduce 
in vitro and in vivo experimentation, while also increasing prediction accuracy and they are not strictly limited in application 
to investigative toxicology. 
 The power of machine-learning approaches in drug discovery is through integration with network modeling (Figure 
5). A well-curated, comprehensive molecular interaction network can reveal causes and effects of protein interactions in 
signaling and metabolic pathways, thus allowing for network-based screening to systematically identify target proteins of a 
drug and its impact (Hsin et al., 2013). 
 
Fig. 5: Enabling technologies for Investigative Toxicology: Application of machine learning / AI (artificial intelligence) 
for the prediction of target activity 
 
3.1.3 AOPs and their role in network models 
AOPs have been more commonly applied in the safety assessment of chemicals but less so in drug discovery. AOPs serve as 
a mostly linear concept to identify measurable key events (KEs). However, AOPs, especially quantitative AOPs, may also 
prove beneficial as a framework to build in silico tools and in vitro batteries for drug discovery (Hartung, 2017b). AOP-based 
networks based on shared KEs are in active development (Knapen et al 2018). Systems biology models, such as neural 
networks have been a focus in drug development but require comprehensive, complex tools for their quantification (Hartung 
et al., 2012, 2017). Although not formally applied thus far, toxicokinetic-toxicodynamic (TKTD) modelling (Tsaioun et al., 
2016; Kretschmann et al., 2012), may prove to be a useful tool to quantify KEs. These models simulate processes leading to 
toxicity in organisms over time, where (a) uptake and elimination rate constants for a NCE/NBE in an organism are 
determined to estimate the time course of a toxicant at a target (e.g. Molecular Initiated Events [MIEs]) and (b) damage 
accrual and recovery rate constants for an effect across biological scales are determined to estimate the time course of an 
effect. 
 
3.1.4 QIVIVE and PBPK/PD 
A quantitative understanding of the progression of biological events from MIEs to adverse outcomes allows us to derive 
tissue-specific points of departure (PoD) from organ-specific in vitro assays assessing perturbations of relevant KEs. The 
PoD is used to mark the beginning of extrapolation to determine risk associated with expected human exposures. Quantitative 
AOPs will help answer what level of in vitro perturbation should be used as a PoD for quantitative in vitro to in vivo 
extrapolations (QIVIVE) (Hartung, 2017a). An understanding of the activity threshold is required that pushes the toxicity 
pathway onward from one molecular event in this pathway to the next and the internal dose of the drug or toxicant that 
affects the probability and severity of an event perturbation. 
PBPK modelling is becoming indispensable for QIVIVE (Basketter et al., 2012; Leist et al., 2014). Specifically, reverse 
dosimetry PBPK is being used to estimate human exposures that lead to concentration-time profiles equivalent to sufficiently 
active concentration-time profiles in vitro (Louisse et al., 2017). Recent efforts in the US EPA ToxCast program6 illustrate 
the integration of in vitro activity concentrations with reverse dosimetry PBPK for risk assessment. In vitro determined 
hepatic clearance and plasma protein binding parameterized a TK model to predict the chemical steady-state concentrations 
(Css) in plasma resulting from repeated daily exposure. Reverse dosimetry PBPK tools were subsequently used to estimate 
human equivalent doses in mg/kg/day required to achieve blood Css levels identical to in vitro bioactive concentrations. 
 
3.1.5 Big Data 
Besides the –omics applications and the concomitant pathway analysis, future use of big data in safety science will 
encompass two fields, early compound (drug candidate) assessment and translation concordance analysis. On the one hand 
mining of large preclinical data sets will result in automated read-across procedures (Hartung, 2016), which will enable the 
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assessment of new chemical structures, including structural moieties for their potential toxicity liabilities. Such tools will 
enable medicinal chemists to guide their hit-to-lead search, not only for criteria of pharmacophore, Drug Metabolism and 
Pharmacokinetics (DMPK) and physico-chemical properties, but also for specific safety aspects, also termed Green 
Toxicology (Maertens et al., 2014; Crawford et al., 2017; Maertens and Hartung, 2018). An example, of how such read-
across approaches might be applied for optimizing drug candidate selection to reduce toxicity liabilities in early phases has 
recently been published (Steger-Hartmann and Pognan, 2018). 
 The other area of interest is the automated analysis of animal-human translation or concordance. Questions such as: 
“tell me how an n-fold decrease in white blood cell count in species x at dose y corresponds with effects in humans?”, with all 
subsequent ramifications (can results be grouped according to preclinical species, pharmacology, mode of action,…) or "what 
is the most sensitive preclinical species for a specific organ toxicity?" can be approached by analyses of big data sets (Clark 
and Steger-Hartmann, 2018).  
 Big data analyses however require: 
• accessibility of large preclinical and clinical data sets, while safeguarding aspects of intellectual property and 
personal data protection  
• automated procedures for data curation 
• integration of controlled vocabularies & ontologies to be able to cross-analyze data 
• quality control of data by scientific experts 
Such efforts can only be achieved via consortia approaches and should be run in parallel to data sharing guidelines and 
principles. Examples of such initiatives are DruSafe7 (Monticello, 2015), eTransafe8 or the request to make data "fair" (= 
“findable, accessible, interoperable, reusable”9) . 
 
3.2 Safety biomarkers  
 
3.2.1 Application and classification of safety biomarkers 
Safety biomarkers for use in Investigative Toxicology fall largely into the category of ‘response biomarkers’ (Amur et al., 
2015). A drug liability identified early in discovery, which shall be monitored and ideally de-risked during non-clinical and 
clinical research requires robust and reliable safety biomarkers of translational relevance to human. The same biomarkers 
would conceivably also support monitoring in patient populations and positively impact the therapeutic safety margins. As 
biomarkers provide valuable information on drug safety, they are increasingly integrated as part of drug discovery and non-
clinical development. Establishing the use of novel safety biomarkers with target organ specificity and mechanistic insight 
for use in non-clinical (Blaauboer et al., 2012) and clinical studies nevertheless remains challenging.  
 Biomarkers include messenger and micro RNAs, proteins, metabolites, clinical chemistry (Brooks et al., 2017) as 
single endpoint measurements or as multiplexed processes in microarray and microfluidic platforms. Whatever the biomarker 
selected, preclinical confirmation on the comparative molecular biology, translational relevance of the mechanism of toxicity, 
target organ and time course with known histopathology in humans is required for later qualification (Matheis et al., 2011). 
The classification of biomarkers as exploratory, probable valid biomarkers and valid biomarkers defines how biomarkers are 
applied in R&D (Chau et al., 2008). With increasing numbers of qualified biomarkers, their classification helps define how 
emerging and future biomarkers can be used to support decision-making and their acceptance by regulatory authorities 
(Edwards et al., 2016). 
 
3.2.2 Safety biomarkers for the three key target organs 
The development of safety biomarkers for the organs which contribute to highest attrition, i.e. heart, liver, and CNS (Central 
Nervous System) has been pivotal for reasons of both the severity and occurrence of these target organ toxicities across many 
classes of drugs (Marrer and Dieterle, 2010). The progress towards the development of biomarkers among these three target-
organ toxicities is highlighted below. 
 
Heart (cardiovascular toxicity) 
Cardiovascular toxicities accounting for ADRs, drug attrition and withdrawal relate to all components of the cardiovascular 
system (Laverty et al., 2011; Valentin et al., 2010) and can be broadly categorized into i) structural damage, ii) functional 
deficits with or without histopathological correlates and iii) altered cell or tissue homeostasis in the absence of obvious 
structural or functional deficits (Wallace et al., 2004). The diversity of ADRs necessitates a range of biomarkers to detect, 
predict and monitor ADRs in non-clinical and clinical testing. Biomarkers of hemodynamic effects include monitoring of 
blood pressure, heart rate, ejection fraction using semi-invasive approaches. Cardiac electrophysiological effects such as QTc 
prolongation or shortening, QRS widening, PR prolongation, arrhythmias such as Torsades de Pointes and ventricular 
fibrillation are detectable via the ECG (Electrocardiogram). For some of these endpoints predictive in vitro screens are well 
established, there is a good relationship between free plasma concentration associated with significant QT 
prolongation/Torsade d Pointes in the clinic and in vitro Ikr IC50 values (Webster et al., 2002). More recently, safety testing 
in stem cell derived cardiomyocytes has been suggested as part of a new integrated risk assessment of pro-arrhythmic liability 
(Sager et al., 2014). Degenerative or inflammatory lesions can be monitored via body fluid sampling and measurement of 
NT-proBNP (N-terminal pro brain natriuretic peptide), miRNAs, CK (creatine kinase), AST (aspartate aminotransferase), 
Troponin, pro-ANP (pro-atrial natriuretic peptide )/BNP (brain natriuretic peptide) in both non-clinical species and human. 
                                                          
7 https://iqconsortium.org/initiatives/leadership-groups/preclinical-safety/  
8 https://www.etransafe.eu 
9 https://www.go-fair.org/fair-principles/ 
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Although, numerous biomarkers of drug-induced cardiotoxicity have been proposed and are being used, some lack sensitivity 
and/or specificity, therefore the quest for mechanism-based cardiotoxicity biomarkers is continuing. 
 
Liver (hepatotoxicity) 
DILI represent one of the most significant ADRs. During drug development, attrition of promising drug candidates due to 
DILI occurs in preclinical and clinical development (Clarke et al., 2016; Pognan, 2018). DILI is classified as either intrinsic, 
with clear dose-dependent hepatocellular injury (Corsini et al., 2012) or more challenging forms of DILI (idiosyncratic) with 
low incidence rates in human and cannot be predicted with current in vitro and in vivo tests. The phenotypic assessment of 
DILI in patients relies on measures of ALT (alanine aminotransferase), AST, ALP (alkaline phosphatase) and BIL (bilirubin). 
Despite wide acceptance, ALT, AST and ALP are not specific measures of liver injury and detection of BIL occurs after 
extensive liver injury has occurred (Church et al., 2018). In non-clinical testing, detection of DILI relies substantially on the 
use of histology (Weaver et al., 2017). 
The use of ALP, ALT and BIL as biomarkers is suboptimal for the detection of human DILI and predicting outcome. Efforts 
to improve upon these liver safety biomarkers have yielded promising, novel biomarkers with additional mechanistic 
information: High mobility group box 1 (HMGB1) for detection of necrosis (Scaffidi et al., 2002) and its acetylated form in 
immune DILI (Lu et al., 2012). The value of these and other novel biomarkers, such as Keratin-18 and miR122, are presented 
in detail elsewhere (Antoine et al., 2013; Clarke et al., 2016; Ward et al., 2014). These novel biomarkers are best defined as 
‘response biomarkers’ and further work is encouraged to extend knowledge towards their translational and predictive value as 
qualified biomarkers of DILI (Matheis et al., 2011). The prospect of translationally relevant safety biomarkers for use in the 
prognosis of DILI outcomes in patients is encouraging (Ozer et al., 2008).  
 
CNS (Neurotoxicity) 
There is a need for more sensitive and specific biomarkers that can help diagnose and predict neurotoxicity, that are relevant 
across animal models and translational to the clinical (Schmidt et al., 2017). Some traditional functional biomarkers with 
established non-clinical to clinical translational value (e.g. electroencephalogram [EEG], electroretinogram [ERG), brainstem 
auditory evoked potential [BAEP]) can be used. Fluid-based biomarkers hold great potential due to the relative ease of 
sampling, such as miRNAs, F2-isoprostanes, translocator protein, glial fibrillary acidic protein, ubiquitin C-terminal 
hydrolase L1, myelin basic protein, microtubule-associated protein-2, and total tau. However, some of these biomarkers (such 
as those in CSF, Cerebrospinal fluid) require invasive sampling or are specific to one disease such as Alzheimer’s, 
Parkinson’s while others require further validation. In addition, neuroimaging methodologies may also provide potential 
biomarkers and coupled with functional, genetic- and protein-based biomarker assessments offer an exciting way forward to 
predict, detect and monitor drug-induced neurotoxicity. 
 
3.2.3 Future Perspectives 
Continued efforts towards the discovery and characterization of novel sensitive and relevant biomarkers to effectively bridge 
from in vitro to non-clinical and clinical testing would strengthen our ability to predict, detect and monitor drug-induced 
organ injuries (Park et al., 2000). The principal challenges ahead include the identification and qualification of these 
biomarkers for use not only as ‘response biomarkers’ but predictive of ADR outcomes and prognosis. 
 
3.3 Novel cell models 
Generating physiologically relevant models is a promising approach to improving our ability to detect and predict drug 
induced toxicity, as well as unravel specific mechanisms of toxicity. Therefore, there is an increasing desire to move away 
from the use of cell lines that form part of screening cascades within the drug discovery process and towards primary cells 
with its known limitations (e.g. limited source, variability, etc.) (Eskes et al., 2017; Pamies et al., 2017, 2018; Coecke et al., 
2007). 
 Consequently, a robust and reproducible and relatively “unlimited” source of cells with defined phenotypes and 
genotypes would greatly benefit the field of toxicity testing and assist in standardizing early investigational toxicological 
research (Pamies and Hartung, 2017). Differentiation of various types of human stem cells into the desired somatic cells 
might be a solution. 
 Moreover, introducing further complexity by culturing cells in 3D, microphysiological and organoid model systems 
is an approach that is growing within the Investigative Toxicology community (Alépée et al., 2014). The theory is that such 
3D and organoid models display more physiologically relevant attributes, including cell polarization, cell–cell or cell–
microenvironment interactions (Anton et al., 2015; Duval et al., 2017; Retting et al., 2018), that are important drivers of 
tissue differentiation and function. Microfluidic and tissue printing techniques have been used to increase complexity of 
tissue models by adding aspects such as co-culture of multiple cell types, with flexibility for compartmentalization and 
higher-order tissue architecture, flow, gradient formation and mechanical strain. This increase in complexity ultimately leads 
to improved functionality and has for various types of approaches been demonstrated in hepatocyte models including 3D 
spheroids (Messner et al., 2013; Bell et al., 2016; Proctor et al., 2017), 3D printed systems (Retting et al., 2018), organoids 
(Huch et al., 2015) and MPS systems (Huh et al., 2010; Vernetti et al., 2016). Each of these systems have added value for 
biological relevance, although their routine implementation for toxicology still remains to be established. 
 
3.3.1 Stem cell models 
Cell lines and primary cells have long been the main source of cells in cell-based experiments. Cell lines provide a relatively 
stable and continuous source of biological material, but are highly variable as to the level that they maintain the features 
associated with their tissue of origin. Cells that are freshly isolated from primary tissue are generally considered a gold 
standard for their physiological relevance. The time span, over which these properties are maintained, however is typically 
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limited. Moreover, physiological properties may disappear under certain storage conditions, logistics around these primary 
cells is cumbersome, and the quality of isolation can be highly variable.  
Induced pluripotent stem cells (iPSCs) hold the promise of a renewable source of cells and would potentially 
provide large numbers of cells with well-characterized physiological properties and with genotypes that correspond to 
specific individuals. These cells potentially hold great value as a toxicity model which incorporates a relatively unlimited 
supply of human cells with defined phenotypes. 
 Today, various cell types are used for iPSC production, e.g. germ lines, liver cells, skin cells and lymphocytes 
(Takahashi and Yamanaka, 2006; Yu et al., 2007; Gadue and Cotsarelis, 2008; Okita et al., 2007; Loh et al., 2009; Aoi et al., 
2008). Various protocols to guide iPSC differentiation towards specific cell lineages have been published. Cell types 
including endothelial cells (ECs) and smooth muscle cells, neuronal cells, cardiomyocytes, hepatocyte like cells could be 
differentiated with specific supplements and growth factors from iPSCs (Patsch et al., 2015; Hu et al., 2011; Mauritz et al., 
2008). Phenotypes of various diseases, such as familial hypercholesterolemia, Wilson´s disease and alpine-1-antitrypsin 
disease have been generated from iPSC derived hepatic cells, which could be used as cellular disease models (Cayo et al., 
2012). Fundamental research on these cells could help our understanding of various disease-types leading to the development 
of novel drugs. 
 Most established for toxicity testing are cardiomyocytes (Millard et al., 2018), with neurons quickly following pace 
(Wevers et al., 2016). The quality of hepatocyte differentiation is progressing. However, expression levels of xenobiotic 
metabolism genes in iPSCs are still not equal to those found in organs or freshly isolated primary cells. Other obstacles 
continue to impede the progress towards using these cells for in vitro toxicology (variability in lines, incomplete 
programming within cell populations, uncharacteristic response to prototype toxicants, etc.). 
 Despite these limitations, iPSC derived cells are now suggested to be used as an alternative source of human cells 
in toxicological screenings and may provide understanding of individual patient ADRs (van Hassselt and Iyengar, 2017), 
where the most advanced example is probably the CIPA (comprehensive in vitro pro-arrhythmic assay) initiative initiated by 
the FDA (Food and Drug Administration) (Wallis et al., 2018). 
 Fully functional organ-specific cells derived from iPSCs will become a valuable tool for drug development or 
evaluation of the contribution of genetic variation to variable responses. Moreover, the technology provides a unique 
opportunity to distinguish between gender, ethnic background and potentially even disease background. The field is 
progressing rapidly, with varying levels of limitations still remaining. However, even though the introduction of induced 
pluripotent or embryonic stem cells for toxicological and pharmacological studies seems inevitable, efforts for 
standardization, validation and regulation are still necessary in order to make them a widely accepted option for toxicological 
and pharmacological studies. 
 
3.3.2 Organoids 
Organoids are a recent paradigm in tissue culture, with culture conditions assuring the preservation of the (adult) stem cell 
niche, while proliferation and differentiation to the essential cellular subtypes of a specific organ still occur. E.g. intestinal 
organoids accurately predict therapy response in cystic fibrosis and were used to establish living biobanks of tumor tissue that 
were genetically stable over time (Artegiani and Clevers, 2018). Whereas these intestinal organoids were expanded from 
primary human cells or human stem cells, pluripotent stem cells have also been used to generate organoids with impressively 
realistic in vivo-like microanatomy for the brain (Lancaster and Knoblich, 2014) and kidney (Takasato et al., 2015; Freedman 
et al., 2015). As of today, many organoid systems have been developed, including liver (Huch et al., 2013; Takebe et al., 
2013), intestine (Spence et al., 2011), thyroid (Antonica et al., 2012), pancreas (Greggio et al., 2013), lung (Lee et al., 2014), 
and retina function (Nakano et al., 2012).  
Whereas most of these systems are currently being mainly used in the context of basic developmental and stem cell 
research or disease modelling (Artegiani and Clevers, 2018), it becomes evident that these technologies start to play a role in 
the field of toxicology. What is required is a full and thorough evaluation of physiological and pharmacological 
characteristics of these organotypic models alongside with human tissues to establish whether such models are “fit-for-
purpose”, i.e. improving the prediction of target organ toxicities (Carragher et al., 2018). The utility of these in vitro models 
can be enhanced by understanding the AOPs/PoT covered by the model of interest (Hartung and McBride, 2011; Kleensang, 
2014; Hartung, 2017b). 
There are obvious hurdles to overcome (Lancaster and Knoblich, 2014; Carragher et al., 2018): 
− artificial organoids currently mimic some, but not all, of the physiological functions of the respective human organs 
(Materne et al., 2013), 
− they lack physiological vasculature and, consequently, whole blood perfusion, which is essential to nutrient supply, 
waste transport and several other physiological processes, including creating a dynamic microenvironment, 
− they lack key cell types, such as immune cells (resident or circulating), and neuronal innervation, 
− primary cell-derived artificial organoids face the shortage of human cell supply, 
− they lack in vivo relevant cellular architecture and cell-cell interactions, 
− they lack mechanical forces, 
− stem cell-derived artificial organoids replicate only the early stages of organ development, remaining “fetal-like” 
due to lack of essential cues for final differentiation. 
Therefore, organoid systems still represent a trade-off between throughput and physiological relevance, and in many cases, 
the effects of a drug are dependent on factors such as metabolic competence or tissue specific distribution and interaction 
which cannot be achieved within single organoids. 
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3.3.3 Microphysiological systems (MPS) 
Within the last 5 to 10 years advances in microfluidic and micro-engineered technology has enabled the development of so 
called organ-on-a-chip models or MPS (Marx et al., 2016; Smirnova et al., 2018; Esch et al., 2015). By applying engineering 
principles, models can now be created that accurately represent the cellular microenvironment of an organ (Bhatia and 
Ingber, 2014). In doing so, cells theoretically retain their physiological phenotype and respond in comparable ways to their in 
vivo counterparts. Application of these models within the Investigative Toxicology and safety assessment process has been 
recently reviewed (Ewart et al., 2018). MPS are cell source agnostic and support various tissue architectures from monolayer 
to 3D and artificial organoids. Because of their specialized microenvironment they have recently been demonstrated as a tool 
that can enhance stem cell maturation (Sances et al., 2018; Ronaldson-Bouchard et al., 2018). While typically of limited 
throughput, higher throughput systems have been developed and applied for toxicity testing of 3D gut tubules and iPSC-
derived neuronal models (Trietsch et al., 2017; Wevers et al., 2016). Multiple organs can be combined on one chip (Wagner 
et al., 2013; Skardal et al., 2017) to investigate the mechanisms that drive organ toxicity at organ cross talk. Finally, the 
impact of biological feedback loops such as the insulin-glucose regulation of liver performance can be studied using the 
respective organ combinations (Bauer et al., 2017). 
Organs-on-chips have also been developed to evaluate drug-induced toxicity (Esch et al., 2015). Organ-specific 
examples are heart-on-a-chip (Zhang et al., 2015) and the lung-on-chip model developed by Huh and coworkers (Huh et al., 
2010). A 3D bio-printed, cell-based mammalian skeletal muscle strip was successfully generated that is able to exert 
muscular force (Cvetkovic et al., 2014). In addition, three-dimensional bio-printed human models of liver, kidney proximal 
tubule, and intestinal tissue have been described for use in modeling native physiology and compound-induced toxicity 
(Nguyen et al., 2016; King et al., 2017; Madden et al., 2018). The progress in MPS hepatocyte culture systems (including 
non-parenchymal co-culture and bio-physical constraints such as oxygen tension) has led to additional improvement of tissue 
and organ level function (Vernetti et al., 2016, 2017; Lee-Montiel et al., 2017). 3D liver and neuronal spheroids have 
successfully been co-cultured on MPS for long term toxicity testing (Materne et al., 2015). Human intestinal organoids, liver 
spheroids, human skin biopsies and monolayer proximal tubular cell barriers have been combined on a four-organ MPS 
platform for evaluation of systemic long term toxicity (Maschmeyer et al., 2015). Hepatic and cardiac cell types have been 
differentiated from iPSCs using MPS (Giobbe et al., 2015). It has been hypothesized, that exposure of in vitro assembled 
premature iPSC-derived organoids to the physiological cues of MPSs, such as perfusion, shear stress, electrical stimulation 
and organoid cross talk in interconnected arrangements might constitute the missing step for their final and complete in vitro 
differentiation. Furthermore, first progress has been made to vascularize microfluidic systems (Schimek et al., 2013; Van 
Duinen et al., 2017). 
Figure 6 schematically illustrates the current cell model landscape and future perspectives as discussed in this 
chapter. 
 
 
Fig. 6: The current cell model landscape 
Traditional systems for evaluation of toxicity include cell line- and primary cell-based models. Developing technologies such as 
3D organoids, bio-printed tissues, and single- and multi-organ MPS will result in models with increased biological relevance, for 
which full validation and routine implementation remain to be established. Human body-on-a-Chips are still at an early research 
stage of their development. 
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3.3.4 Envisioned progress of in vitro models 
The described progress in human iPSC generation at robust large scale, their differentiation into a broad variety of premature 
organ-specific somatic cell based artificial organoids and steady increase of number of organ equivalents on MPS platforms 
has created a historically unique opportunity for the introduction of humanized models in safety assessment (Miller and 
Shuler, 2016; Xiao et al., 2017; Edington et al., 2018). The combination of these three approaches may well lead to the 
establishment of personalized minute equivalents of a healthy donor or a patient-on-a-chip. Figure 7 summarizes the long-
term vision of using such MPS-based personalized patient equivalents for studies, mimicking Phase 1 and Phase 2 clinical 
trials. 
 
 
Fig. 7: Sketching a roadmap towards “clinical trials” on a chip 
Assembly of minute personalized “body” equivalents on a chip derived from cells of individual healthy donors or patients at 
ethically acceptable conditions is still a hypothetical multistep procedure exploring different aforementioned technologies. 
 
Eventual success along this roadmap may enable us to perform individualized studies mimicking clinical trials of a 
particular donor using statistically relevant numbers of almost identical replicates of donor or patient “bodies” on the chips. 
This somehow matches with the current situation of using inbred genetically identical laboratory animals in preclinical 
evaluation, with the only difference that such miniaturized “bodies”-on-a-chip are of personalized human origin. 
Furthermore, it might support head-to-head analysis of the outcome of the real donor or patient study with its body-on-a-chip 
counterparts. Finally, the use of “body” equivalents from donors and patients of different gender, ethnic groups and genetic 
backgrounds eventually allow to exactly evaluate the impact of that background parameters on safety and efficacy of a 
NCE/NBE in the preclinical setting, which illustrates the high potential of such tools for the drug development cycle (Marx et 
al., 2016). 
 
3.4 Imaging technologies 
The past decades have seen enormous development and integration of high-content imaging in Investigative Toxicology 
departments, (van Vliet et al., 2014; Uteng et al., 2014). With the integration of a variety of small molecule fluorescent 
probes, this has allowed the detection of a variety of biochemical perturbations and live/dead endpoint measurements. For 
example, probes have been used to follow the accumulation of fatty acids in cells leading to steatosis (Germano et al., 2015), 
one of the critical endpoints of DILI. Fluorescent bile acids have been applied to determine the accumulation of bile acids as 
a consequence of bile acid transport inhibition and may contribute to compounds with liability for drug-induced cholestasis 
(Germano et al., 2015). Likewise, fluorescent probes have been used for assessment of phospholipidosis (Morelli et al., 
2006), oxidative stress, and mitochondrial membrane potential (Billis et al., 2014). Within the pharmaceutical industry this 
high-content imaging approach has become an essential tool within the field of predictive toxicology with the aim to design 
and prioritize drug candidates with a superior safety profile (Persson and Hornberg, 2016). While the technologies have 
primarily used 2D cell systems (either cell lines or primary cells; Pampaloni et al., 2007), the challenge for the future is to 
capture this in advanced 3D cell models and allow sufficient resolution for single-cell-based quantification of probe activity. 
Novel high-content imaging machines still have the limitation to capture the fluorescence of cells in the center of 
multicellular 3D spheroids. Challenges for the future are to bring light-sheet microscopy to the level of high-content 
screening and integrate this in screening labs (Joshi and Lee, 2015). This will then allow the detailed analysis of biochemical 
changes in complex MPS. Novel approaches involve phenotypic screening of cell morphologies allowing the quantification 
of hundreds of (related) parameters in parallel (Joshi and Lee, 2015; Leary et al., 2018). Further challenges include the 
integration of other mechanistic biomarkers in high-content imaging strategies that would represent key events of AOPs. 
 Further advances in molecular imaging capability and deployment are also continuing through the development of 
label-free bio-imaging of tissues and cells (and potentially single cells and organelles) using mass spectrometry (MS) based 
approaches (Passarelli and Ewing, 2013).  
 
ALTEX preprint  
published December 20, 2018 
doi:10.14573/altex.1808181 
 
14 
 
3.5 Omics profiling 
Omics-technologies, which gained more prominence and relevance over the last few years, can be divided in four parts and 
focus on different steps in the generation of bioactive molecules: Genomics, Transcriptomics, Proteomics and Metabolomics. 
Systematic studies on transcriptome analysis within large consortia and industry settings have helped establish extensive 
datasets of drug-induced transcriptome profiles in different target organs as well as in vitro cells. This is exemplified by the 
TG-GATEs10 and DrugMatrix11 datasets that are available in the public domain (Igarashi et al., 2015; Ganter et al., 2005). 
The initial hope of toxicogenomics as the solution for ultimate prediction of target organ toxicity has not been fully fulfilled 
as the technology and the diversity of transcriptional profiles has been more complex than anticipated (Pognan, 2007). While 
toxicogenomics-based prediction gene profiles have been established for several adverse outcomes, including genotoxicity 
testing (Ellinger-Ziegelbauer et al., 2009), a widespread generic application in drug safety testing has not been implemented. 
Generally, toxicogenomics is applied to support the mechanistic understanding of identified target organ toxicities. With 
RNA sequencing, being the current major tool in transcriptome analysis, and sequencing becoming much cheaper, new 
applications of toxicogenomics are emerging and may require new attention and funding. In addition, improved 
bioinformatics tools that integrate large omics datasets into co-regulated gene networks, allow the quantitative analysis of the 
association between such gene networks and adverse outcomes (Stiehl et al., 2017; Sutherland et al., 2018). There is a rapid 
development of sequencing strategies, where chromatin-immuno-precipitation (ChIP) sequencing will contribute to a further 
refinement of the transcription factors that drive these transcriptional networks in different target tissue. These 
complementary sequencing approaches should ultimately define the quantitative relationships between both safe and adverse 
ranges of pathway activation that will determine the safety margins. The IMI TransQST project will contribute to these 
quantitative systems toxicology evaluations12. 
 In concert with transcriptome analysis, sensitive proteomics platforms have also evolved that have allowed the 
analysis of cell and tissue proteomes under healthy and disease settings and after drug exposure (Cox and Mann, 2011). In 
particular, phosphoproteomics has allowed the assessment of early signals of cell signaling activation in relation to drug 
exposure (Pines et al., 2011). To date (phospho)-proteomics is not yet a common tool in drug safety assessment and 
Investigative Toxicology. However, integration of proteomics with transcriptomics has helped to get a more precise 
understanding of drug action (Puigvert et al., 2013). Recent integration of biology information with proteomics has allowed 
the identification of drug targets of a large panel of kinase inhibitors (Klaeger et al., 2017). The integration of activity-based 
target profiling in Investigative Toxicology with the help of proteomics will further clarify the spectrum of off-targets of 
candidate drugs and contribute to the improved drug safety prediction. 
 Metabolomics is defined as analysis (identification and quantification) of active metabolites, including 
carbohydrates, lipids and more complex bioactive molecules, such as hormones. Its role in toxicology is increasing (Bouhifd 
et al., 2013; Ramirez et al., 2013), fueled also by increasing quality assurance (Bouhifd et al., 2015). The metabolome can be 
determined in human and animal matrices (e.g. blood, plasma, urine or sweat) with the focus on the entire body but also on 
organ-specific toxicity. Moreover, organ specific metabolomes for in vitro systems have been reported (Ramirez et al., 2013). 
 In parallel, targeted approaches for metabolomics have been developed, with increased sample throughput, 
enhanced analytical robustness and facilitated data analyses. Targeted metabolomics carries the promise of a high 
translational potential for clinical studies. An example for targeted metabolomics is the application of multiplexed LC 
(Liquid Chromatography) MS/MS methods for bile acid analysis (both unconjugated and conjugated) for the assessment of 
cholestatic or steatotic potential of drug candidates (Schadt et al., 2016). While the metabolome analysis of plasma and urine 
require animal testing, it is recommended to consider the 3Rs strategy (focus on reduction) and therefore include the “omics” 
technology in animal studies. Hence in vitro metabolomics are an important step to use “omics” data avoiding animal studies 
and therefore support the 3Rs strategy (focusing on replacement). 
 
3.6 Intracellular sensors 
Perturbations of normal cell physiology leading to perturbation of biology culminate in adverse outcome. There is a limited 
set of cellular perturbations that will drive this adversity. The establishment of AOPs and AOP networks, with the help of 
omics and cell biology, has already defined some critical pathways related to toxicity. This involves both biochemical 
perturbations as well as cellular disturbances that drive cell signaling and onset of adaptive rescue programs, or alternatively 
the onset of pathways that drive cellular demise. Cell biologists and toxicologists have taken advantage of this information 
and integrated biomarker genes tagged with fluorescent proteins that represent various adaptive cellular stress response 
pathways. Bacterial artificial chromosome genome editing technologies have allowed the GFP (Green fluorescent protein) -
tagged expression of sensors, transcription factors and downstream target genes of different cellular adaptive stress response 
pathways, including the Nrf2-mediated oxidative stress pathway, the p53-mediated DNA damage response pathway, NFκB-
mediated inflammatory signaling and the ATF4 and XBP1-based unfolded protein response (Wink et al., 2014). These 
fluorescent reporter cell systems can be integrated with high-content imaging and allow the dynamic analysis of stress 
response pathway activation (Wink et al., 2017). Wink and collaborators recently demonstrated the application of a panel of 
these reporters in the prediction of DILI, using a panel of >120 DILI compounds (Wink et al., 2018). A full coverage of 
cellular components that drive the adverse responses of drugs would contribute to the toolbox to evaluate drug safety.  
 Developments in cell and molecular biology have allowed the refinement of fluorescent protein probes based on 
fluorescent resonance energy transfer (Ni et al., 2017). This allows the dynamic imaging of cell signaling activity. The 
integration of such tools in high-throughput microscopy setups would allow a refined understanding of the balance between 
cell adaptation and adversity and has been used in safety assessment of drugs (Shuhendler et al., 2014). 
                                                          
10 http://toxico.nibio.go.jp/english/index.html. 
11 https://ntp.niehs.nih.gov/drugmatrix/index.html 
12 http://transqst.org/ 
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4 Challenges 
 
4.1 Definitions, terminology and the need for ontologies 
Toxicology as a subject is important in many industry sectors in addition to the pharmaceutical area, such as the chemical 
industry, cosmetics, consumer products as well as food industry. Moreover, it also plays an important role in environmental 
health. Since every sector discusses specific needs and issues, the terminology around toxicology varies widely. Therefore, it 
is not surprising how differently the term ‘Investigative Toxicology’, together with its related keywords, is used in the 
respective context. Even when discussed by toxicologists within the pharmaceutical industry, ‘Investigative Toxicology’ is 
used sometimes with different meaning. Hence the challenge that emerged in the beginning of the Think Tank was a common 
understanding of the keywords of Investigative Toxicology. The need to harmonize descriptions of the keywords to enable 
easier discussion among all stakeholders became obvious. This is particularly important in the effort to implement 
Investigative Toxicology also into the regulatory process when discussing safety aspects with regulatory authorities. 
 As aforementioned and much discussed during the workshop, a holistic definition of Investigative Toxicology in 
drug development could be the complementary discipline to ‘regulatory toxicology’, that includes all aspects of scientific 
investigations into drug candidates starting with screening and selection of tolerable compounds (prospective approach) and 
leading to the mechanistic elucidation of adverse effects observed in preclinical or clinical phases (retrospective approach)’. 
Whether (or how) this definition can be translated to academia and other industry sectors will be seen in the near future. Such 
translation is of high importance since both approaches (prospective and retrospective) are currently in a transition phase, 
triggered by exponentially evolving testing options (e.g. complex human in vitro models, gene targeting, or enhanced 
screening possibilities). For all stakeholders, a common more precise understanding of needs and objectives of these 
approaches is necessary to successfully align development efforts in academia and industry. Common advancement is 
necessary to deliver comprehensive tools that can support all stakeholders according to their objectives.  
 Furthermore, the terminologies in the context of ‘Investigative Toxicology’ need to be harmonized since different 
(sub)disciplines may have different understanding of key terms, including biomarkers, safety assessment, mode of action, 
off-target/on-target toxicity, hampering the focused integration of new technologies. But also in the field of regulatory 
toxicology, ontologies of toxicological observations are not fully harmonized (Hardy et al., 2012a,b). How this can be 
improved was demonstrated in the ontology discussion within the IMI eTOX Project. Histopathology Ontology was 
developed, intended to standardize histopathology findings, and it has now been made openly available (Ravagli et al., 2017). 
It is a key enabler, making searches possible on one of the most important data types in toxicology studies and provides a 
database for new in silico and in vitro models13.  
 Further aspects that were found to be critical and challenging for an effective development of new tools (e.g. 
models, methods) include the definition of performance standards that lead to successful proof of concept studies. These need 
to be clearly defined, to demonstrate the value of an evolving complex cell model or entire testing method for the respective 
objective. In turn, proof of concept studies may form the basis of the critical aspect of validation of a test method. In best 
case, a formal validation as the entrance door for regulatory use needs to be clearly defined to not only deliver reproducible 
results, but to ensure the results are relevant and informative for hazard identification and risk assessment (Amur et al., 
2015). 
 Many keywords that emerged in the field in recent years are barely defined across stakeholders/sectors. For 
example, translational biomarkers and AOPs are frequently used in innovative publications (Antoine et al., 2013). However, 
at least in the case of safety biomarkers, the underlying understanding is still diverse, ranging from very specific (e.g. FDA 
approved kidney toxicity marker (Brott et al., 2014)) to broad use (e.g. gene expression pattern to define toxicity pathway 
(Ferrario et al., 2014)). Also, the OECD-introduced AOP concept describes the dissection of molecular toxicity pathways and 
defines key molecular events (OECD, 2017). But to make it a useful concept for risk assessment, hence allowing a 
differentiation between adaptation and adversity across the different sectors, a common understanding is needed, that finally 
leads to quantitative read-outs or thresholds. 
 Taken together, the Think Tank discussion, although initiated by one industry sector only, clearly showed the need 
to harmonize the use of key terms in the field of Investigative Toxicology. A common understanding of the relevant 
vocabulary was stated as the basis to drive this discipline. 
 
4.2 Study design 
Before starting an investigative study or incorporating the investigative part into a regulatory GLP toxicology study, the 
expectation and the conclusions that might be drawn from the results should be anticipated, clearly described in a study plan 
and scientifically justified. This puts more weight on the scientific justification of the experimental design and does not 
necessarily need a full validation or description of the methods in regulatory guidelines. In case a model is more advanced, 
performance of multi-center studies to prove the robustness of the method is a key requirement. Thus, the community of 
Investigative Toxicologists together with the developers of the new models shall enable the pre-validation of these models. 
 For stand-alone in vitro studies a fit-for-purpose validation (see chapter 5), including scientifically justified 
negative and positive controls is key, whereas for experimental biomarkers, histopathological correlates might be sufficient. 
In the field of Investigative Toxicology, it is very often an iterative investigation cycle with multiple steps that lead to the 
generation of hypothesis and finally to the generation of mechanistic data that support the mechanism of toxicity. 
                                                          
13 http://etransafe.eu/histopathology-ontology/ 
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 Another important aspect regarding the design of a preclinical safety study is the question whether to use disease 
models or not. Although disease models are not often used in animal toxicity studies, the underlying disease may be 
important to identify the most critical key events, as well as thresholds, leading to an ADR (Morgan et al., 2013). The 
technologies for human in vitro disease models as described in chapter 2.1.2 as well as animal disease models humanized by 
gene editing technologies (see chapter 2.2.3) will provide new translational approaches for the identification of the mentioned 
critical key events. This idea combined with the aspect of human diversity may eventually lead to the development of 
individual patient-derived cell models that may be included into a clinical trial of the respective patient. Whether these cell 
models still need to serve as organ toxicity models is debatable, since the concept of AOPs is not restricted to individual 
organs and in best case an appropriate cell model may depict the fundamental toxicity mechanism in the body across different 
organs. However, the most important challenge for the AOP concept is the quantitative aspect (Hartung, 2017b). What is the 
cut-off value at which read-out or key event indicates a safety risk? In other words, for example for the pharmaceutical 
industry the question is: How can one define a safe human dose from an AOP investigation? This question is still 
unanswered. Considering the importance of this aspect, Investigative Toxicology should strive to make this a powerful tool 
for answering this question. 
 
4.3 Communication 
The Think Tank discussed intensively the need for ‘disruptive technologies’. The meaning of "disruptive" in this context is a 
technology, which has the potential to entirely change the current toxicity strategies which mainly rely on animal studies for 
risk assessment. "Big data", which has become a buzz word across very different industry sectors triggers hopes to contribute 
to such disruptive technologies, such as in silico modelling for precise prediction of specific organ toxicities (Mulliner et al., 
2016b). However, valuable expertise of handling and connecting big data with relevant information lies outside the life 
science community (Haslehurst and Johnson, 2018). For example, technology and knowhow of social network and internet 
companies may be useful to develop new strategies to translate toxicity data into meaningful context. Therefore, a suggestion 
is to bring together different industry sectors for new discussions about needs and opportunities that the internet and big data 
offers to toxicology. Examples for such new fields of collaboration are smart phone apps which found their entry into the 
storage, tracking and sharing of diagnostic data for diabetes patients demonstrating an improved self-care (Osborn et al., 
2017). IT technology companies like Apple, Amazon and Google already made initial steps towards life science and the 
healthcare sector e.g. by successfully applying their automated deep learning algorithms to diagnostic image analysis for the 
detection of retinopathy (Gulshan et al., 2016).  
 
 
5 Qualification and Validation 
 
Over the last few years, many novel cell systems and technologies have emerged on to the market, most with little validation 
or supportive data. As a discipline, Investigative Toxicology needs to become proactive finding the right balance between 
project-oriented issue resolution and ready to use/fit-for-purpose technology evaluation. Problem orientation also requires 
moving away from the formal requirement of validation, although important, as this often slows down the implementation of 
3Rs methods, towards a “fit-for-purpose14” evaluation of new approaches. The ICH Note for guidance on Non-clinical Safety 
Studies for the Conduct of Human Clinical trials for Pharmaceuticals (ICH M3 (R2) states that "(…), consideration should be 
given to use of new in vitro alternative methods for safety evaluation. These methods, if validated and accepted by all ICH 
regulatory authorities, can be used to replace current standard methods." But what is "validated"? ICH makes almost no 
reference to validation, except for analytical methods (ICH Q2A, Q2B, M10). Validation is defined by OECD (2005) as “the 
process by which the reliability and relevance of a particular approach, method, process or assessment is established for a 
defined purpose”. 
 The European Medicines Agency (EMA) (EMA, 2016) defines reliability as "a measure of the extent that a test 
method can be performed reproducibly over time when using the same protocol". The reliability of current pivotal in vivo 
toxicology studies should be assured by compliance with GLP. Even though GLP principles are general and well applicable 
in many areas, it became evident that GLP was mainly tailored for in vivo methods available at the time of their development 
and need to be adapted to the requirements of in vitro assays (OECD, 2004). More recently, the EU Joint Research Center 
(JRC), at the request of the OECD, has developed a guidance on Good In Vitro Method Practices - GIVIMP (OECD, 2018). 
The GIVIMP document describes the factors relevant to reliability and relevance of in vitro data generated for human safety 
assessment purposes and has been written with different users in mind, including GLP test facilities and research laboratories 
developing new in vitro methods. 
 Relevance is defined by EMA (2016) as "the extent to which the test correctly measures or predicts the biological 
effect of interest". So, how should relevance be established? According to EMA, "Relevance incorporates consideration of 
the accuracy (e.g. concordance with comparable validated test method with established performance standards) of a test 
method". However, this assumes that the existing "validated test method" is adequately relevant, which is not always the case 
for some in vivo animal test systems. A direct example of this is AOP-based in vitro skin sensitization testing; where 
concordance of the in vitro results with the standard in vivo mouse local lymph node assay (LLNA) is poor (Dumont et al., 
2016) due to both limited relevance and high variability of the reference data. In this case, concordance of the in vitro data 
with human data is much better, because concordance of the in vivo LLNA with human data is relatively poor (Natsch and 
Emter, 2015) as already been shown for the guinea pig assay preceding the LLNA (Luechtefeld et al., 2016; Adriaens et al., 
2014; Hoffmann, 2015). In the meantime several testing and assessment strategies have been published (Urbisch et al., 2015; 
                                                          
14 "Fit-for-purpose" is defined as a level of validation which proves that the assay or biomarker is sufficient for use in a 
particular defined context. It does not require a regulatory submission (for reference see footnote 13). 
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Roberts and Patlewicz, 2018), which contributed to the development of a consolidated IATA (integrative approach to testing 
and assessment) for skin sensitization by OECD (2014).  
For the pharmaceutical sector EMA and FDA have put in place a qualification process that addresses innovative 
drug development methods and tools developed for a specific intended use in a pharmaceuticals research and development 
context (non-clinical or clinical studies) (EMA, 2014). These are voluntary, scientific pathways leading to a regulatory 
conclusion that an innovative method or tool has data to support its specific context of use in drug development (Ohno, 
2002). The qualification concept also applies to the submission of biomarkers, however in this case it is independent of the 
specific test or assay performing the measurement15. 
Overall, while the terminology (i.e. qualification versus validation) differs and the processes evolve to keep pace with 
scientific progress and to benefit from it, the underlying purpose and principles of qualification and validation remain 
relatively constant as laid down in the modular approach to validation and in the OECD Guidance Document (Hartung et al., 
2004; OECD, 2005). As described by Hartung et al. (2013), the validation procedure should follow fit-for-purpose 
approaches. A procedure that strictly follows the modular approach system, comparing in vitro data with animal data still 
relies on the concept of one-to-one replacement. New concepts need to be developed, taking into account combination of 
assays (IATA) and human data. A combination of in silico and in vitro might be the future to solve this problem. 
 
 
6 Recommendation: the way forward 
 
Investigative Toxicology is a recent discipline in drug safety assessment that strives for a holistic view on properties of 
candidate molecules (NCEs/NBEs) and their predicted effect in humans by combining in silico, in vitro, in vivo and clinical 
data making use of innovative technologies and novel approaches (Figure 8). Thus, it should be seen as complementary to 
regulatory toxicology that is often confined by International guidelines. Investigational Toxicology can embrace novel 
technologies more readily. Thereby, it is able to evaluate of these technologies and produces evidence for their further use 
also in the regulatory context. 
 
Fig. 8: General view on how Investigative 
Toxicology will contribute to the development of 
new drugs 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
In a prospective manner, efforts in Investigative Toxicology focus on early screening tools allowing for candidate selection as 
well as de-risking activities, where tailored work packages aim to unravel mechanisms of adverse events observed during 
pre-clinical and clinical stages and assessment of potential ways forward. The key to success of these activities is close 
interaction with experts from academia and regulatory bodies. The objective is to elaborate robust, reliable and accepted 
Investigative Toxicology concepts for decision making by virtue of multiple and diverse tools, technologies and readouts. 
In the rapidly evolving field of drug development, with new drug modalities arising, new chemical spaces being explored, 
complex pharmacological strategies being pursued and diseases and pathways involving the immune system becoming key, it 
is instrumental that safety assessment is continuously innovated to be able to address new challenges arising from these 
trends. Together with high regulatory burden, cost and time pressures and the need to reduce animal testing demands for 
novel concepts, strategies and tools, Investigative Toxicology plays a key role. Collaborative efforts in the pre-competitive 
space are considered necessary to explore and establish these innovative new tools and concepts.  
An important role is played by education, in order to create a new generation of scientists (Daneshian et al., 2011). Novel 
technologies, innovative scientific approaches, and new terminologies ask for modern and up-dated ways of teaching-
learning (Flecha, 2018). Professional knowledge and expertise in this discipline is mandatory, considering that the possible 
target audience is wide and goes from undergraduate students to graduates (M.Sc., Ph.D., Post Docs), and from Academia 
and Industry scientists, and Regulators. Teaching must go hand in hand with research, and common strategies and novel 
approaches are urgently required. Currently, university graduate and post-graduate level courses in life-science, that provide 
adequate training, are few and the implementation is fundamental for a competency-based education, and consequently social 
impact.  
  
                                                          
15 https://www.fda.gov/Drugs/DevelopmentApprovalProcess/DrugDevelopmentToolsQualificationProgram/ 
BiomarkerQualificationProgram/default.htm, accessed 24-Jul-2018 
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Among the key themes are: 
− Making use of clinical and real-world data to inform and improve testing algorithms early on, establishment of 
modeling approaches allowing to predict human response from in vitro 
− New human cell models, such as microphysiological systems and human Organs-on-Chips allowing for safety and 
efficacy assessment in vitro and generation of a cellular therapeutic index, modeling disease aspects by use of 
patient-derived tissues and iPSCs for patient stratification, the ability to perform phenotypic screens and 
identification of translational biomarkers  
− Image-based technologies and omics readouts to support in vitro to in vivo assessment as well as back translation 
from clinical specimen to cell models, to understand safety and disease as well as patient-specific, personalized 
aspects. Monitor AOPs and identify key events from early discovery stages in vitro up to clinical phases. 
− Focus on quantitative systems biology level-based risk assessments that integrate diverse pharmacological and 
toxicological data sets, including from advanced humanized models and human tissue, to underpin mechanistic 
understanding of adverse drug effects and permit translational, exposure-based modeling of toxicological impact. 
− Education based on new integrated teaching strategy  
The participants of the workshop envisage an increasing importance of Investigative Toxicology in supporting the entire drug 
development process. Cross-industry collaboration in the pre-competitive part of this work helps to accumulate experiences 
on novel approaches faster and more reliably. This process can impact on the complementation and replacement of traditional 
methods in regulatory toxicology. This also means that the promotion of new technologies supports a lesser reliance on 
animal studies moving the industry to more human-relevant assessment approaches. 
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